David T. Curiel, MD, PhD

Washington University in St. Louis (WU)

Our interest is in the development of virus-based therapeutics for inherited and acquired disorders. In this regard, both gene therapy and virotherapy approaches have been applied principally for the context of neoplastic diseases. Our group embodies a strong bench-to-bed translational fucus whereby laboratory-derived strategies are applied for the context of human Phase 1 clinical trials. We also seek to develop useful surrogate endpoint analyses (ex. imaging) that will enable us to gain the maximal amount of useful information from these human trials.